Priya Rastogi, MD, discusses a substudy evaluating a whole-exome sequencing, tumor-informed ctDNA MRD assay in TNBC after neoadjuvant chemotherapy.
Priya Rastogi, MD
Advertisement
Priya Rastogi, MD, is an associate professor of medicine at the University of Pittsburgh School of Medicine, as well as a medical oncologist at the University of Pittsburgh Medical Center Hillman Cancer Center
Articles by Priya Rastogi, MD
Priya Rastogi, MD discusses MonarchE: primary overall survival results of adjuvant Abemaciclib plus Endocrine therapy For HR+, HER2-, high-risk early breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/19
2
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
3
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
4
Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
5